Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: The effect of assay conditions and regioselective stimulation by α-naphthoflavone, terfenadine and testosterone

Pharmacogenetics

Volumn 8, Issue 2, 1998, Pages 137-155

  Mäenpää, Jukka ^a,b   Hall, Stephen D ^b   Ring, Barbara J ^a   Strom, Stephen C ^c   Wrighton, Steven A ^a,b  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

CYP3A; Hepatocytes; Midazolam; Stimulation

Indexed keywords

ALPHA NAPHTHOFLAVONE; CUMENE HYDROPEROXIDE; CYTOCHROME P450 3A; CYTOCHROME P450 ISOENZYME; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; MIDAZOLAM; TERFENADINE; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; FETUS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IONIC STRENGTH; LIVER MICROSOME; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; ARYL HYDROCARBON HYDROXYLASES; BENZENE DERIVATIVES; BENZOFLAVONES; BUFFERS; CALCIUM CHLORIDE; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MAGNESIUM CHLORIDE; MICROSOMES, LIVER; MIDAZOLAM; NADP; OXIDOREDUCTASES, N-DEMETHYLATING; TERFENADINE; TESTOSTERONE;

EID: 0031960329     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Boxenbaum HG, Riegelman S, Elashoff RM. Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm 1974; 2: 123-148.
2. Brian WR, Sari M-E, Iwasaki M, Shimada T, Kaminsky L, Guengerich FP. Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry 1990; 29: 11280-11292.
3. Darbar D, Dell'Orto S, Mörike K, Wilkinson GR, Roden DM. Dietary salt increases first-pass elimination of oral quinidine. Clin Pharmacol Ther 1997; 61:292-300.
4. Fabre G, Rahmani R, Placidi M, Combalbert J, Covo J, Cano J-P et al. Characterization of midazolam metabolism using human hepatic microsomal fractions and hepatocytes in suspension obtained by perfusing whole human livers. Biochem Pharmacol 1988; 37:4389-4397.
5. Gemzik B, Halvorson MR, Parkinson A. Pronounced and differential effects of ionic strength and pH on testosterone oxidation by membrane-bound and purified forms of rat liver microsomal cytochrome P-450. J Steroid Biochem 1990; 35:429-440.
6. Ghosal A, Satoh H, Thomas PE, Bush E, Moore D. Inhibition and kinetics of cytochrome P4503 A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metab Dispos 1996; 24:940-947.
7. Gillam EMJ, Guo Z, Ueng Y-F, Yamazaki H, Cock I, Reilly PEB et al. Expression of cytochrome P450 3A5 in Escherichia coli: Effects of 5′ modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. Arch Biochem Biophys 1995; 317:374-384.
8. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994; 47:1643-1653.
9. Guengerich FP. Analysis and characterization of enzymes. In: Hayes AW, ed. Principles and methods of toxicology. New York: Raven Press, 1994: 1259-1313.
10. Guengerich FP. Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, ed. Cytochrome P450: structure, mechanism, and biochemistry. New York: Plenum Press. 1995: 473-536.
11. Guengerich FP, Shimada T, Yun C-H, Yamazaki H, Raney KD, Thier R et al. Interactions of ingested food, beverage, and tobacco components involving human cytochrome P4501A2, 2A6, 2E1, and 3A4 enzymes. Environ Health Perspect 1994; 102 (suppl 9):49-53.
12. Huang M-T, Chang RL, Fortner JG, Conney AH. Studies on the mechanism of activation of microsomal benzo(a)pyrene hydroxylation by flavonoids. J Biol Chem 1981; 256:6829-6836.
13. Imaoka S, Imai Y, Shimada T, Funae Y. Role of phospholipids in reconstituted cytochrome P450 3A form and mechanism of their activation of catalytic activity. Biochemistry 1992; 31: 6063-6069.
14. Ingelman-Sundberg M, Hagbjörk A-L, Ueng Y-F, Yamazaki H, Guengerich FP. High rates of substrate hydroxylation by human cytochrome P450 3A4 in reconstituted membranous vesicles: Influence of membrane charge. Biochem Biophys Res Commun 1996; 221:318-322.
15. Johnson EF, Schwab GE, Vickery LE. Positive effectors of the binding of an active site-directed amino steroid to rabbit cytochrome P-450 3c. J Biol Chem 1988; 263:17672-17677.
16. Jurima-Romet M, Crawford K, Cyr T, Inaba T. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 1994; 22:849-857.
17. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, Levy RH. Human liver carbamazepine metabolism; role of CYP3A4 and CYP2C8 in 10, 11-epoxide formation. Biochem Pharmacol 1994; 47:1969-1979.
18. Kitada M, Kamataki T, Itahashi K, Rikihisa T, Kato R, Kanakubo Y. Immunochemical examinations of cytochrome P-450 in various tissues of human fetuses using antibodies to human fetal cytochrome P-450, P-450 HFLa. Biochem Biophys Res Commun 1985; 131:1154-1159.
19. Kocarek TA, Schuetz EG, Strom SC, Fisher RA, Guzelian PS. Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug Metab Dispos 1995; 23:415-121.
20. Koley AP, Buters JTM, Robinson RC, Markowitz A, Friedman FK. Differential mechanisms of cytochrome P450 inhibition and activation by α-aphthoflavone. J Biol Chem 1997; 272: 3149-3152.
21. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989; 38:89-96.
22. Lasker JM, Huang M-T, Conney AH. In vivo activation of zoxazolamine metabolism by flavone. Science 1982; 216:1419-1421.
23. Lasker JM, Huang M-T, Conney AH. In vitro and in vivo activation of oxidative drug metabolism by flavonoids. J Pharmacol Exp Ther 1984; 229:162-170.
24. Lee CA, Lillibridge JH, Nelson SD, Slattery JT. Effects of caffeine and theophylline on acetaminophen pharmacokinetics: P450 inhibition and activation. J Pharmacol Exp Ther 1996; 277: 287-291.
25. Levy RH, Yerby MS. Effects of pregnancy on antiepileptic drug utilization. Epilepsia 1985; 26 (suppl 1):S52-S57.
26. Li AP, Rasmussen A, Xu L, Kaminski DL. Rifampicin induction of lidocaine metabolism in cultured human hepatocytes. J Pharmacol Exp Ther 1995; 274:673-677.
27. Nordblom GD, White RE, Coon MJ. Studies on hydroperoxide-dependent substrate hydroxylation by purified liver microsomal cytochrome P-450. Arch Biochem Biophys 1976; 175: 524-533.
28. Pearce R, Greenway D, Parkinson A. Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. Arch Biochem Biophys 1992; 298:211-225.
29. Pelkonen O. Differential inhibition of aryl hydrocarbon hydroxylase in human foetal liver, adrenal gland and placenta. Acta Pharmacol Toxicol 1977; 41:306-316.
30. Potenza CL, Pendurthi UR, Strom DK, Tukey RH, Griffin KJ, Schwab GE et al. Regulation of the rabbit cytochrome P-450 3c gene. J Biol Chem 1989; 264:16222-16228.
31. Ring BJ, Binkley SN, Roskos L, Wrighton SA. Effect of fluoxetine, norfluoxctine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1′-hydroxy midazolam formation in vitro. J Pharmacol Exp Ther 1996a; 275, 1131-1135.
32. Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Cerimele BJ et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996b; 276:658-666.
33. 5 in the process. Arch Biochem Biophys 1994; 314: 234-241.
34. Schwab GE, Raucy JL, Johnson EF. Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylation by α-naphthoflavone. Mol Pharmacol 1988; 33:493-499.
35. Shet MS, Fisher CW, Holmans PL, Estabrook RW. Human cytochrome P450 3A4: Enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase. Proc Natl Acad Sci USA 1993; 90:11748-11752.
36. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV et al. Activation of CYP3A4: Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 1994; 33:6450-6455.
37. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994; 271:549-556.
38. van der Hoeven TA, Coon MJ. Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. J Biol Chem 1974; 249:6302-6310.
39. Wiebel FJ, Leutz JC, Diamond L, Gelboin HV. Aryl hydrocarbon (benzo(a)-pyrene) hydroxylase in microsomes from rat tissues: Differential inhibition and stimulation by benzo-flavones and organic solvents. Arch Biochem Biophys 1971; 144:78-86.
40. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992; 22:1-21.
41. Wrighton SA, VandenBranden M, Stevens JC, Shipley LA, Ring BJ, Rettie AE, Cashman JR. In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab Rev 1993; 25:453-484.
42. Wrighton SA, Ring BJ. Inhibition of human CYP3 A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharmaceut Res 1994; 11:921-924.
43. Yamazaki H, Ueng Y-F, Shimada T, Guengerich FP. Roles of divalent metal ions in oxidations catalyzed by recombinant cytochrome P450 3A4 and replacement of NADPH-cytochrome P450 reductase with other flavoproteins, ferredoxin, and oxygen surrogates. Biochemistry 1995; 34:8380-8389.
44. Yang CS, Brady JF, Hong J-Y. Dietary effects on cytochromes P450, xenobiotic metabolism, and toxicity. FASEB J 1992; 6: 737-744.
45. Yun C-H, Song M, Ahn T, Kim H. Conformational change of cytochrome P450 1A2 induced by sodium chloride. J Biol Chem 1996; 271:31312-31316.